MARKET

SANA

SANA

Sana Biotechnology, Inc.
NASDAQ
8.41
-0.17
-1.98%
Opening 10:04 04/25 EDT
OPEN
8.22
PREV CLOSE
8.58
HIGH
8.47
LOW
8.22
VOLUME
212.52K
TURNOVER
0
52 WEEK HIGH
12.00
52 WEEK LOW
2.745
MARKET CAP
1.85B
P/E (TTM)
-5.7761
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SANA last week (0415-0419)?
Weekly Report · 3d ago
Sana Biotechnology EVP and President of R&D Resigns
TipRanks · 6d ago
Weekly Report: what happened at SANA last week (0408-0412)?
Weekly Report · 04/15 09:11
Weekly Report: what happened at SANA last week (0401-0405)?
Weekly Report · 04/08 09:11
Weekly Report: what happened at SANA last week (0325-0329)?
Weekly Report · 04/01 09:11
Weekly Report: what happened at SANA last week (0318-0322)?
Weekly Report · 03/25 09:11
Weekly Report: what happened at SANA last week (0311-0315)?
Weekly Report · 03/18 09:11
Sana Biotechnology: Now In Overbought Territory
Shares of Sana Biotechnology, Inc. Are up over 30% since pricing a secondary offering in February 2024. The company is focused on developing engineered cells to treat diseases. Sana has three clinical programs in Phase 1 trials, with promising results in the treatment of B-cell cancer and type I diabetes. Sana uses a hypoimmune technology platform to create cells that evade immune detection.
Seeking Alpha · 03/17 11:35
More
About SANA
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.

Webull offers Sana Biotechnology Inc stock information, including NASDAQ: SANA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SANA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SANA stock methods without spending real money on the virtual paper trading platform.